Hospira (NYSE:HSP) is a provider of specialty injectable pharmaceuticals and infusion technologies. Despite its regulatory troubles of the past five years, Hospira is strategically one of the best positioned companies in the biopharma industry. The company's unique generic injectable capacity and its ability to develop biosimilars, both play into healthcare cost reductions around the world. We believe we are near the tail end of Hospira's regulatory woes and the stock will have a multi-year run, doubling in the next two years. The company is likely to see additional gains through several product launches over the next five years creating strong cash flows, providing opportunities to augment its pipeline and make investments in overseas manufacturing to boost margins above...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|